个人简介

---

职称：教授
学科专业：病理学与病理生理学
研究方向：炎症和肿瘤干细胞、外泌体液态活检和个体化肿瘤治疗
行政职务：肿瘤精准医学和病理研究所所长
电子邮箱：haozhang@jnu.edu.cn
个人信息：张灏，MD, Ph.D., 教授、博士生导师、博士后指导教授、肿瘤精准医学和病理研究所所长。研究领域：专注我国高发恶性肿瘤的基础研究和转化应用：1）炎癌通路调控肿瘤干性和肿瘤微环境的机制；2）新型肿瘤标志物和治疗靶点；3）外泌体液体活检和外泌体疫苗。担任Annals of Medicine（Taylor & Francis出版社）副主编、Cancer Letters（Elsevier 出版社）和Scientific Report（Nature出版社）编委，国内期刊《转化医学杂志》执行编委。作为PI承担多项国家、省部级自然科学基金、产学研以及国际合作等项目。获批十余项临床诊疗领域的国内外专利，并申报和主持了多项相关的临床试验。以第一完成人获广东省科技进步奖、广东省医学科技奖、中国产学研合作创新奖、全国十佳消化道领域临床研究奖等。担任《中国抗癌协会肿瘤标志专业委员会》、《中国抗癌协会肿瘤代谢委员会》、《中国临床肿瘤协会（CSCO）胰腺癌专家委员会》常委，《广东省抗癌协会肿瘤标志物委员会》、《广东省抗癌协会肿瘤代谢委员会》、《广东省肿瘤药理学会》、《广东省抗癌协会抗肿瘤药物专业委员会》副主委，《亚太医学生物免疫学会肿瘤学分会》副主委，《中国抗癌协会肿瘤标志专业委员会外泌体技术专家委员会》主委，首个《外泌体研究转化和临床应用专家共识》专家组组长。近5年来在Clin Cancer Res，PNAS，Oncogene, JCI, J Pathology等国际主流杂志发表多篇有影响的学术成果,并应邀撰写多篇综述。主编和参编多部由Springer 出版社、科学出版社和人民卫生出版社等出版的肿瘤、外泌体和嵌合RNA领域的学术专著。

---

获奖及荣誉

---

1.广东省医学科技奖二等奖（第一完成人），2019；
2.中国消化道领域临床研究十佳奖（第一完成人），2020；
3.广东省科技进步奖二等奖（第一完成人），2020；
4.中国产学研合作创新奖（第一完成人），2020。

---

研究经历

---

2018-至今暨南大学，教授
2008-2018，汕头大学医学院，教授，附属肿瘤医院/肿瘤研究中心
2004-2008，美国UT MD Anderson 癌症中心，讲师，分子肿瘤学系/遗传系
1999-2004，美国贝勒医学院，博士后研究员，分子细胞学系
1994-1999，日本岛根医科大学，博士，发育生物学/细胞生物学
1988-1994，中国医科大学附属盛京医院，住院医/主治医/讲师，内科内分泌科
1984-1987，中国医科大学，硕士，内科内分泌学
1979-1984，中国医科大学，本科，临床医学

---

主要论文

---

特邀综述(*通讯作者)
1.Ning Z, Gan J, Chen C, Zhang D,Zhang H*: Molecular functions and significance of the MTA family in hormone-independent cancer.Cancer Metastasis Rev. 2014, 33(4): 901-919. (invited review)
2.Chang L, Ni J, Zhu Y, Pang B, Graham P,Zhang H*, Li Y*: Liquid biopsy in ovarian cancer: recent advances in circulating extracellular vesicle detection for early diagnosis and monitoring progression.Theranostics.2019: 9(14): 4130-4140. (review)
3.Zheng L, Wang L, Gan J,Zhang H*: RNA activation: promise as a new weapon against cancer.Cancer lett. 2014, 355(1): 18-24. (invited review)
4.Ma L, Yao Z, Deng W, Zhang D,Zhang H*: The Many Faces of MTA3 Protein in Normal Development and Cancers.CurrProteinPept Sci.2016, 17(8): 726-734.(invited review)
5.Du L, Ning Z,Zhang H*,Liu F*: Corepressor metastasis-associated protein 3 modulates epithelial-to-mesenchymal transition and metastasis.Chin J Cancer.2017: 36(1):28. (invited review)
6.Yang Z ,Zhang H, Kumar R* : Regulation of E-cadherin.Breast Cancer Online. 2005, 8(03): e15. (Cambridge Univeristy Press, www. camridge. org). (invited review)(共同第一作者)
7.Su J, Concilla A, Zhang D, Zhao F, Shen F,Zhang H*, Zhou F*: PIWI-interacting RNAs: Mitochondria-based Biogenesis and Functions in Cancer.Genes Dis.2020, Available online.
8.Yong Li, Xupeng Bai, Jie Ni,Hao Zhang, Duan Wei, and Peter Graham. Exosomes and breast cancer drug resistance.Cell Death & Disease.2020.
9.林宇晟, 甘进锋, 江钰琛, 王飞寒,张灏*: 外泌体标志物和肿瘤液体活检的研究进展及现状。中国癌症防治杂志, 2019, 11(02): 99-103. (review)
10.刘情, 郑琳,张灏*: 人源性肿瘤组织异种移植(PDX)模型的研究进展。转化医学杂志, 2014, 10. 3969, 2095-3097.
11.黄裔腾, 殷秀凯, 钟雪云,张灏*: 食管鳞癌模式动物的研究进展。世界华人消化杂志, 2011, 19(16): 1704-1710.
12.李宗泰,张灏*: 外周血游离DNA甲基化检测: 食管鳞癌早期诊疗的新机遇。转化医学杂志, 2012, 1(1)：45-48.
13.李金平, 宁志丰, 刘复兴,张灏*: 老药新用, 小分子药物二甲双胍的抗肿瘤研究进展。中国生化药物杂志, 2016 , 36 (8) : 16-21
14.王姝宏，余幼林，李凯，林宇晟，甘进锋，谢飞凌，李勇，黄思铨，张灏*.外泌体在肿瘤和极端条件中的作用和检测。中国癌症防治杂志, 2020, 12(3)：239-243.
15.吴晓，杨海军，高社干，周福有，张灏*. 原发性食管小细胞癌的研究及诊疗现状。食管疾病，2020, 2(1), 8-12.
专家共识
1.张灏等。《外泌体研究、转化和临床应用专家共识》，转化医学杂志，2018。
论著摘选(*通讯作者)
1.WangL, Du L, Xiao X, LinY, ZhuJ, YaoZ, WangS, GuoY, ChenY, GearyK, PanY, ZhouF, GaoS, ZhangD, YeungSC,ZhangH*.Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling.Oncogene.2021, DOI:10.1038/s41388-021-01682-z.
2.Wang L, Xiong X, Yao Z, Zhu J, Lin Y, Lin W, Li K, Xu X, Guo Y, Chen Y, Pan Y, Zhou F, Fan J, Chen Y, Gao S, Sai-Ching Jim Yeung andZhang H*.Chimeric RNA ASTN2-PAPPAas aggravates tumor progression and metastasis in human esophageal cancer.Cancer Letters.2021, 501:1-11.
3.Xiong X, Ke X, Wang L, Yao Z, Guo Y, Zhang X, Chen Y, Pang CP, Schally AV,Zhang H*. Splice variant of growth hormone-releasing hormone receptor drives esophageal squamous cell carcinoma conferring a therapeutic target.Proc Natl Acad Sci USA, 2020, 117(12): 6726-6732.
4.Wang S, Lin Y, Xiong X, Wang L, Guo Y, Chen Y, Chen S, Wang G, Lin P, Chen H, Sai-Ching J Yeung, Edwin Bremer,Zhang H*. Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer.Clin Cancer Res. 2020, 26(18):4921-4932.
5.Chu YL, Li H, Ng PLA, Kong ST, Zhang H, Lin Y, Tai WCS, Yu ACS, Yim AKY, Tsang HF, Cho WCS, Wong SCC. The potential of circulating exosomal RNA biomarkers in cancer.Expert Rev Mol Diagn.2020, 20(7):665-678.
6.Beibei Xu, Xunjin Jiang, Jing Xiong, Jun Lan, Yuan Tian, Linhai Zhong, Xinquan Wang, Ning Xu, Hanwei Cao, Wenqing Zhang,Hao Zhang, Xiaoting Hong, Yan-Yan Zhan, Yandong Zhang, Tianhui Hu. Structure-Activity Relationship Study Enables the Discovery of a Novel Berberine Analogue as the RXRα Activator to Inhibit Colon Cancer.J Med Chem,2020; 63(11):5841-5855.
7.Bhagelu R. Achyut,Zhang H*, Kartik Angara, Nahid F. Mivechi, Ali S. Arbab, Lan Ko*: Oncoprotein GT198 Vaccination Delays Tumor Growth in MMTV-PyMT Mice.Cancer Lett. 2020, 476:57-66.
8.Du L, Wang L, Gan J, Yao Z, Lin W, Li J, Guo Y, Chen Y, Zhou F, Jim Yeung SC, Coppes RP, Zhang D,Zhang H*: MTA3 Represses Cancer Stemness by Targeting the SOX2OT/SOX2 Axis.iScience.2019; 22:353-368.
9.Yao Z, Du L, Xu M, Li K, Guo H, Ye G, Zhang D, Coppes RP,Zhang H*: MTA3-SOX2 Module Regulates Cancer Stemness and Contributes to Clinical Outcomes of Tongue Carcinoma.Front Oncol.2019, 9:816.
10.Ke X, Xiong X, Lin Y,Zhang H*:Chimeric RNA and Exosomes-Based Liquid Biopsy.Methods Mol Biol.2020; 2079:211-218.
11.Tamiya H, Kim H, Klymenko O, Kim H, Feng Y, Zhang T, Han JY, Murao A, Snipas SJ, Jilaveanu L, Brown K, Kluger H,Zhang H, Iwai K, Ronai ZA*. SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.J Clin Invest.2018; 128(1): 517–530.
12.Wang W, Lim KG, Feng M, Bao Y, Lee PL, Cai Y, Chen Y,Zhang H, Marzese D, Hoon DSB, Yu Q*: KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer.Mol Cancer Ther. 2018; 17(9):1973-1983.
13.Gan J, Ke X, Jiang J, Dong H, Yao Z, Lin Y, Lin W, Wu X, Yan S, Zhuang Y, Chu WK, CaiR, Zhang X, Cheung HS, Block NL, Pang CP, Schally AV,Zhang H*: Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1-STAT3/NF-κB signaling.Proc Natl Acad Sci USA. 2016, 113(51):14745-14750.
14.Lin Y,Dong H,Deng W,Lin W,Li K,Xiong X,Guo Y,Zhou F,Ma C,Chen Y,Ren H,Yang H,Dai N,Ma L,Meltzer SJ,Yeung SJ,Zhang H*:Evaluation of Salivary Exosomal Chimeric GOLM1-NAA35 RNA as a Potential Biomarker in Esophageal Carcinoma.Clin Cancer Res. 2019, 25(10): 3035-3045.
15.Dong H, Ma L, Gan J, Lin W, Chen C, Yao Z, Du L, Zheng L, Ke C, Huang X, Song H, Kumar R, Yeung SC,Zhang H*. PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2.Oncogene. 2017: 36(3): 410-422.
16.Dong H, Xu J, Li W, Gan J, Lin W, Ke J, Jiang J, Du L, Chen Y, Zhong X, Zhang D, Yeung SC, Li X,Zhang H*. Reciprocal androgen receptor/interleukin-6 crosstalk drives oesophageal carcinoma progression and contributes to patient prognosis. J Pathol.2017: 241(4): 448–462.
17.Wang L, Li K, Lin X, Yao Z, Wang S, Xiong X, Ning Z, Wang J, Xu X, Jiang Y, Liu D, Chen Y, Zhang D,Zhang H*.: Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis.Cancer Lett.2019, 450: 22-31.
18.Feng Y, Ke C, Tang Q, Dong H, Zheng X, Lin W, Ke J, Huang J, Yeung SC,Zhang H*: Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.Cell Death Dis.2014, 27, 5: e1088.
19.Li Z, Zou X, Xie L, Chen H, Chen Y, Yeung SC,Zhang H*: Personalizing risk stratification by addition of PAK1 expression to TNM staging: improving the accuracy of clinical decision for gastroesophageal junction adenocarcinoma.Int J Cancer.2015, 136(7): 1636-1645.
20.Zhang H, Lin W, Kannan K, Luo L, Li J, Chao PW, Wang Y, Chen YP, Gu J, Yen L*: Aberrant chimeric RNA GOLM1-MAK10 encoding a secreted fusion protein as a molecular signature for human esophageal squamous cell carcinoma.Oncotarget.2013, 4(11),2135-2143.
21.Yu J, Lin Y, Xiong X, Li K, Yao Z, Dong H, Jiang Z, Yu D, Yeung SJ,Zhang H*: Detection of Exosomal PD-L1 RNA in Saliva of Patients With Periodontitis.Front Genet., 2019, 10: 202.
22.Wang L, Li W, Li K, Guo Y, Liu D, Yao Z, Lin X, Li S, Jiang Z, Liu Q, Jiang Y, Zhang B, Chen L, Zhou F, Ren H, Lin D, Zhang D, Yeung SJ,Zhang H*: The oncogenic roles of nuclear receptor coactivator 1 in human esophageal carcinoma.Cancer Med., 2018, 7: 5205-5216.
23.Tang Q, Li G, Wei X, Zhang J, Chiu JF, Hasenmayer D, Zhang D,Zhang H*: Resveratrol-induced apoptosis is enhanced by inhibition of autophagy in esophageal squamous cell carcinoma.Cancer Lett.2013, 336(2): 325-337.
24.You Y, Chen Y, Zheng X, Meltzer SJ,Zhang H*: Aberrant methylation of the PTPRO gene in peripheral blood as a potential biomarker in esophageal squamous cell carcinoma patients.Cancer Lett.2012, 315(2): 138-144.
25.Zhang H, Singh RR, Talukder AH, Kumar R*: Metastatic tumor antigen 3 is a direct corepressor of the Wnt4 pathway.Genes Dev.2006, 20(21): 2943-2948.
26.Zhang H, Kuang SQ, Liao L, Zhou S, Xu J*: Haploid inactivation of the amplified-in-breast cancer 3 coactivator reduces the inhibitory effect of peroxisome proliferator-activated receptor gamma and retinoid X receptor on cell proliferation and accelerates polyoma middle-T antigen-induced mammary tumorigenesis in mice.Cancer Res.2004, 64(19): 7169-7177.
27.Zhang H, Stephens LC, Kumar R*: Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.Clin Cancer Res.2006, 12(5): 1479-1486.
28.Zhou C*, Wu YL, Chen G, Liu X, Zhu Y, Lu S, Feng J, He J, Han B, Wang J, Jiang G, Hu C,Zhang H, Cheng G, Song X, Lu Y, Pan H, Zheng W, Yin AY. BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer.J Clin Oncol.2015, pii: JCO. 2014. 59. 4424.
29.Kumar R*,Zhang H, Holm C, Vadlamudi RK, Landberg G, Rayala SK: Extranuclear coactivator signaling confers insensitivity to tamoxifen.Clin Cancer Res.2009, 15(12): 4123-4130.
30.Wang RA,Zhang H, Balasenthil S, Medina D, Kumar R*: PAK1 hyperactivation is sufficient for mammary gland tumor formation.Oncogene.2006, 25(20): 2931-2936.
31.Peng M,Zhang H, Jaafar L, Risinger JI, Huang S, Mivechi NF, Ko L*: Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem.2013, 288(46): 33387-33397.
32.Goo YH, Na SY,Zhang H, Xu J, Hong S, Cheong J, Lee SK, Lee JW*: Interactions between activating signal cointegrator-2 and the tumor suppressor retinoblastoma in androgen receptor transactivation.J Biol Chem.2004, 279(8): 7131-7135.
33.Kuang SQ, Liao L,Zhang H, Pereira FA, Yuan Y, DeMayo FJ, Ko L, Xu J*: Deletion of the cancer-amplified coactivator AIB3 results in defective placentation and embryonic lethality.JBiol Chem.2002, 277(47): 45356-45360.
34.Tong Z, Li M, Wang W, Mo P, Yu L, Liu K, Ren W, Li W,Zhang H, Xu J, Yu C*: Steroid Receptor Coactivator 1 Promotes Human Hepatocellular Carcinoma Progression by Enhancing Wnt/beta-Catenin Signaling.JBiol Chem.2015. M115. 640490.
35.Kuang SQ, Liao L,Zhang H, Lee AV, O'Malley BW, Xu J*: AIB1/SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice.Cancer Res.2004, 64(5): 1875-1885.
36.Chu WK, Law KS, Chan SO, Yam JC, Chen LJ,Zhang H, Cheung HS, Block NL, Schally AV*, Pang CP*. Antagonists of growth hormone-releasing hormone receptor induce apoptosis specifically in retinoblastoma cells.Proc Natl Acad Sci USA.2016 , 113(50).
37.Gururaj AE, Singh RR, Rayala SK, Holm C, den Hollander P,Zhang H, Balasenthil S, Talukder AH, Landberg G, Kumar R*: MTA1, a transcriptional activator of breast cancer amplified sequence 3.Proc Natl Acad Sci USA. 2006, 103(17): 6670-6675.
38.Klionsky DJ et al: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).Autophagy.2016, 12(1): 1-222. (coeditor)
39.Chen T, Chen Q, Xu Y, Zhou Q, Zhu J,Zhang H, Wu Q, Xu J, Yu C*: SRC-3 is required for CAR-regulated hepatocyte proliferation and drug metabolism.J Hepatol.2012, 56(1): 210-217.
40.Zhang S, Zeng D, Peng Y, Yang Y, Zhuang X, Li Z, Wang M, Chen L,Zhang H^*,Cancer-related fatigue and chemotherapy-associated adverse effects: correlation with TNF-α, IL-1 and 17-hydroxycorticosteroids.Future Oncol. 2014, 10(9): 1619-26.
学术著作
1.《Encyclopedia of Cancer 》(癌症百科全书）《Springer出版社》编委；
2.《肿瘤急症治疗例析》《人民卫生出版社》主编，2020；
3.《Chimeric RNA: Methods and Protocols》《Springer出版社》编委；
4.《乳腺癌》《人民卫生出版社》副主编；
5.《细胞外囊泡》《科学出版社》编委，2019；
6.《肿瘤标志物》《人民卫生出版社》编委，2019；
7.《肿瘤标志物通讯》（外泌体专刊）《中国抗癌协会出版》主编，2018。

---

学术兼职

---

1.Annals of Medicine（Taylor & Francis出版社）副主编
2.Cancer Letters（Elsevier 出版社）编委
3.Scientific Report（Nature出版社）编委
4.《转化医学杂志》执行编委
5.《Frontier inOncology》外泌体专刊客座主编
6.Cancer Research,Clinical Cancer Research,Oncogene & PNAS等杂志审稿专家
7.《胰腺癌诊治指南》撰写组专家
8.《中国抗癌协会肿瘤标志专业委员会外泌体技术专家委员会》主任委员
9.《广东省肿瘤药理学会》副主任委员
10.《广东省抗癌协会抗肿瘤药物专业委员会》副主任委员
11.《亚太医学生物免疫学会肿瘤学分会》副主任委员
12.《广东省抗癌协会肿瘤代谢委员会》副主任委员
13.《广东省抗癌协会肿瘤标志物委员会》副主任委员
14.《中国抗癌协会肿瘤标志专业委员会》常务委员
15.《中国抗癌协会肿瘤代谢委员会》常务委员
16.《中国临床肿瘤协会（CSCO）胰腺癌专家委员会》常务委员
17.《中国医药生物技术协会组织生物样本库委员会》理事
18.《中国医师协会肿瘤医师分会委员会食管癌学组》委员
19.《中国民族卫生协会临床医学分会》常务理事

---